Healthcare
Blackstone in China orthopedics play
The Blackstone Group has picked up a significant stake in Chinese medical devices company Xinrong Best Medical Instrument. Financial details were not disclosed but the deal is understood to be worth around $100 million.
India Value Fund picks 10% stake in Biocon research unit
India Vaue Fund Advisors (IVFA) has bought a 10% stake in Syngene International, the research unit of Indian bio-pharmaceuticals firm Biocon, for INR3.8 billion ($62 million).
Xiaomi Ventures backs China health products maker
Xiaomi Ventures, a corporate VC unit of Chinese mobile phone maker Xiaomi, has paid $25 million for a 20% stake in iHealth, an offshore unit of healthcare electronics maker Andon Health.
Temasek wins approval to buy Intas stake from ChrysCapital
Temasek Holdings has received approval from the Competition Commission of India (CCI) to acquire a stake in Intas Pharmaceuticals from ChrysCapital Partners.
VCs back Zai Lab drug development model
Few VC firms are keen to invest in China's early-stage drug discovery space because the development cycle is long and risky. Taking a new drug from clinical testing to commercialization often takes 7-10 years and the success rate in China is less than...
China stem cell storage firm launches $813m M&A fund
Zhongyuan Union Stem Cell Bio-engineering, a Chinese stem cell storage service operator, has partnered with China Yinhong Capital to launch an industry M&A fund with a target of RMB5 billion ($813 million).
OrbiMed commits $15m to China's GC-Rise Pharma
OrbiMed has committed $15 million in Series B funding to GC-Rise Pharmaceutical, a Chinese healthcare services provider.
Tencent pumps $70m into China healthcare networking site
Tencent Holdings has invested $70 million into dxy.com, a Chinese networking and information-sharing site for healthcare professionals
China's Zai Lab raises $30m Series A round
Qiming Venture Partners has led a $30 million Series A round of funding for Zai Lab, a Shanghai-based biotech drug developer, with participation from KPCB, Sequoia Capital and TF Capital.
Hony raises $528m with another part exit from CSPC Pharma
Hony Capital has made its second partial exit from CSPC Pharmaceutical Group in three months, selling an 11% stake in the Hong Kong-listed Chinese generic drugs maker for HK$4.01 billion ($528 million).
CITIC PE exits Jialin Pharma via trade sale to Luye Pharma
CITIC Private Equity will exit a 10.26% stake in Beijing Jialin Pharmaceutical after Luye Pharma Group, a Chinese drug maker, agreed to buy a majority stake in its industry peer.
Advent supports Australia radiology merger
Advent Private Capital has created the fourth-largest radiology group in Australia by bringing together two independent diagnostics businesses, Lake Imaging and South Coast Radiology.
Sequoia invests $139m in Chinese medical equipment maker
Sequoia Capital has acquired a 7% stake in Jiangsu Yuyue Medical Equipment & Supply, a Chinese medical equipment manufacturer, for RMB856 million ($139 million).
CITIC PE scraps plans for Biosensors takeover
CITIC Private Equity has abandoned plans for a takeover of Singapore-listed Biosensors International, although it will remain an active investor in the medical device manufacturer.
Walden Riverwood leads $8m Series A for Japan's Atonarp
Walden Riverwood Ventures has led an $8 million Series A round of funding for Atonarp, a Japanese developer of chemical sensors.
Sabre leads $8m round for Indian dermatology specialist
Sabre Partners as led an $8 million Series B round of funding for Vyome Biosciences, an Indian bio-pharmaceutical company that specializes in dermatology.
Qualcomm backs India's Portea Medical
Qualcomm Ventures, the venture investment unit of US chip-maker Qualcomm, has invested in India's Portea Medical, a provider of in-home healthcare services. The financial details of the transaction were not disclosed.
Shares in PE-backed Healthscope climb 5.2% on ASX debut
Shares in Healthscope,the Australian hospital operator backed by TPG Capital and The Carlyle Group, rose 5.2% to A$2.21 at the end its first day of trading yesterday following the largest Australian IPO in four years.
TPG, Carlyle to price Healthscope IPO at upper-end of range - report
TPG Capital and The Carlyle Group are to price shares in Australian hospital chain Healthscope at A$2.10 a share - the upper-end of the target range, generating A$2.25 billion ($2.12 billion).
China's JD Capital launches medical, energy funds
JD Capital has launched three renminbi-denominated funds to invest in the medical and energy sectors.
China M&A funds: Double team
Keen to consolidate their fragmented industries, Chinese companies are partnering up with PE firms to launch M&A funds. But do the GPs have the right skills and are third-party LPs willing to come on board?
Town Health International Medical to invest in Chinese PE fund
Town Health International Medical Group, a Hong Kong-listed dental clinics operator, has contributed RMB15.5 million ($2.5 million) to a PE fund launched by a unit of the Guizhou provincial government.
Partial exit for PE investors as Luye Pharma raises $764m
CDH Investments, CITIC Private Equity, New Horizon Capital and GIC Private have made partial exits from Luye Pharma Group as the Chinese drug maker raised HK$5.91 billion ($764 million) through its Hong Kong IPO.
CITIC Capital leads acquisition of US dental firm
CITIC Capital Partners has acquired US-based dental business DDS LAB for an undisclosed sum. The Chinese PE firm has completed approximately 15 deals in the US but this is its first as lead investor.